Prime Therapeutics discusses the challenges health plans face in expanding access to GLP-1 therapies while managing rising costs

Real-world research highlights patient persistence as a critical factor in achieving the long-term benefits of GLP-1 therapies

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

In the latest episode of the “Pharmacy Friends” podcast, hear from Prime Therapeutics experts about how the fast-moving pipeline is changing how patients, providers and payers prepare for...

Unlock high-touch outreach Help members and their prescribers make better decisions about medicines through this clinical intelligence hub that delivers actionable insights, flexible levels of data...

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.